Clinical Trials Browser

Interventional × Bronchiolitis Obliterans Syndrome × 1 year × Clear all

Bronchiolitis Obliterans Syndrome, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT07535008 2026-04-16

Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

Phase NA Not yet recruiting

45 enrolled

Bronchiolitis Obliterans Syndrome

NCT01804686 2026-04-13

CAN3001

Phase 3 Recruiting

700 enrolled

LymphoidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Mantle-Cell

NCT04959175 2026-04-09

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Phase 1/2 Recruiting

320 enrolled

Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT07354074 2026-03-23

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

Phase 2 Not yet recruiting

50 enrolled

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Leukemia, Leukemia, Myelogenous, Chronic, BCR-ABL Positive

NCT02386800 2026-03-16

CINC424A2X01B Rollover Protocol

Phase 4 Active not recruiting

279 enrolled

MyeloidOther hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Polycythemia Vera, Thalassemia, Leukemia, Myeloid, Acute, Primary Myelofibrosis

NCT04710576 2026-03-16

AGAVE-201

Phase 2 Active not recruiting

241 enrolled 11 charts 3 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT05327023 2026-01-26

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Phase 1/2 Recruiting

430 enrolled

Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT04294641 2026-01-23

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

Phase 2 Completed

10 enrolled 15 charts

Other hematologic neoplasm

Bronchiolitis Obliterans Syndrome, Hematologic Neoplasms

NCT04063215 2026-01-15

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

Phase 1/2 Completed

24 enrolled 67 charts

Lymphoid

Brain Injuries, Traumatic, Bronchiolitis Obliterans Syndrome, Cerebral Palsy, Lymphoma, Follicular, Trauma, Nervous System, Intracranial Hemorrhages, Stroke, Hypoxia-Ischemia, Brain

NCT06271616 2025-12-26

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

Phase 2 Recruiting

40 enrolled

Bronchiolitis Obliterans Syndrome

NCT03774082 2025-12-11

REACH 5

Phase 2 Completed

46 enrolled 21 charts

Lymphoid

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease, Lymphoma, Follicular

NCT03790332 2025-10-21

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Phase 1/2 Completed

59 enrolled 2 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

NCT05951777 2025-09-29

Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

Phase 2 Recruiting

51 enrolled

Lymphoid

Brain Injuries, Traumatic, Bronchiolitis Obliterans Syndrome, Lymphoma, Follicular, Trauma, Nervous System, Intracranial Hemorrhages

NCT03112603 2025-08-12

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)

Phase 3 Completed

330 enrolled 32 charts 2 FDA

Bronchiolitis Obliterans Syndrome, Graft vs Host Disease

Clinical Trials

ASC4INDIA

Dental Cleaning to Prevent Chronic Graft-Versus-Host Disease

CAN3001

Phase I/II Study to Reduce Post-transplantation Cyclophosphamide Dosing for Older or Unfit Patients Undergoing Bone Marrow Transplantation for Hematologic Malignancies

Study to Determine the Efficacy and Safety of Asciminib in Pediatric Patients With Ph+ CML-CP

CINC424A2X01B Rollover Protocol

AGAVE-201

Donor Lymphocyte Infusion After Allogeneic Hematopoietic Cell Transplantation for High-Risk Hematologic Malignancies

Front Line Ibrutinib Without Corticosteroids for Newly Diagnosed Chronic Graft-versus-Host Disease

A Clinical Trial to Determine the Safety and Efficacy of Hope Biosciences Autologous Mesenchymal Stem Cell Therapy for the Treatment of Traumatic Brain Injury and Hypoxic-Ischemic Encephalopathy

Ibrutinib for the Prevention of Chronic Graft-Versus-Host Disease in Patients Undergoing Donor Stem Cell Transplant

REACH 5

Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

Autologous Adipose-Derived Mesenchymal Stem Cells for Chronic Traumatic Brain Injury

A Study of Ruxolitinib vs Best Available Therapy (BAT) in Patients With Steroid-refractory Chronic Graft vs. Host Disease (GvHD) After Bone Marrow Transplantation (REACH3)